Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Programmed Cell Death 1 Receptor"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 153
Tytuł:
Gut microbiome for predicting immune checkpoint blockade-associated adverse events.
Autorzy:
Hu M; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Lin X; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Sun T; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Shao X; Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou, 221009, China.
Huang X; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Du W; Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou, 221009, China.
Guo M; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Zhu X; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Zhou Y; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Tong T; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Guo F; Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
Han T; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Wu X; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Shi Y; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai, 200030, China.
Xiao X; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. .
Zhang Y; Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou, 221009, China. .
Hong J; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China. .
Chen H; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China. .
Pokaż więcej
Źródło:
Genome medicine [Genome Med] 2024 Jan 19; Vol. 16 (1), pp. 16. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms*/drug therapy
Gastrointestinal Microbiome*
Antineoplastic Agents, Immunological*/therapeutic use
Drug-Related Side Effects and Adverse Reactions*
Immune System Diseases*
Lung Neoplasms*/drug therapy
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; RNA, Ribosomal, 16S/genetics ; Vitamin K 2/therapeutic use ; Immunotherapy/adverse effects ; Programmed Cell Death 1 Receptor ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Autorzy:
Li L; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Chen L; Chengdu Medical College, Chengdu, China.
Yan L; Chengdu Medical College, Chengdu, China.
Guo Y; Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Li F; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Fan M; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lan M; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lai X; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Zhou J; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Huang Y; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xu P; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lang J; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Feng M; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. freda_.; Department of Clinical Oncology, the Third People's Hospital of Sichuan, Chengdu, China. freda_.
Pokaż więcej
Źródło:
Radiation oncology (London, England) [Radiat Oncol] 2023 Jul 04; Vol. 18 (1), pp. 109. Date of Electronic Publication: 2023 Jul 04.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents, Immunological*/therapeutic use
Head and Neck Neoplasms*/drug therapy
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Programmed Cell Death 1 Receptor ; Immune Checkpoint Inhibitors/therapeutic use ; Neoplasm Recurrence, Local/etiology ; Chemoradiotherapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Apoptosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
Autorzy:
Mutlu H; Department of Oncology, Istinye University School of Medicine, Istanbul, Turkey.
Bozcuk H; Department of Oncology, Lara Medicalpark Hospital, Antalya, Turkey.
Artaç M; Department of Oncology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey.
Eser İ; Department of Thoracic Surgery, Lara Medicalpark Hospital, Antalya, Turkey.
Pokaż więcej
Źródło:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Apr; Vol. 19 (Supplement), pp. S6-S11.
Typ publikacji:
Meta-Analysis; Journal Article; Review
MeSH Terms:
Lung Neoplasms*/therapy
Antineoplastic Agents, Immunological*/therapeutic use
Small Cell Lung Carcinoma*/drug therapy
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Programmed Cell Death 1 Receptor ; Network Meta-Analysis ; Etoposide/therapeutic use ; B7-H1 Antigen ; Platinum/therapeutic use ; Carboplatin/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer.
Autorzy:
Abedian Kalkhoran H; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands. h.abedian_.; Department of Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands. h.abedian_.
Zwaveling J; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
Storm BN; Department of Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands.
van Laar SA; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
Portielje JE; Department of Internal Medicine - Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.
Codrington H; Department of Pulmonary Diseases - Pulmonic Oncology, Haga Teaching Hospital, The Hague, The Netherlands.
Luijten D; Department of Pulmonary Diseases - Pulmonic Oncology, Haga Teaching Hospital, The Hague, The Netherlands.
Brocken P; Department of Pulmonary Diseases - Pulmonic Oncology, Haga Teaching Hospital, The Hague, The Netherlands.
Smit EF; Department of Pulmonary Disease, Leiden University Medical Centre, Leiden, The Netherlands.
Visser LE; Department of Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands.; Department of Hospital Pharmacy, Erasmus Medical Centre, Rotterdam, The Netherlands.; Department of Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Mar 14; Vol. 23 (1), pp. 247. Date of Electronic Publication: 2023 Mar 14.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Antineoplastic Agents, Immunological*/adverse effects
Middle Aged ; Humans ; Aged ; Immune Checkpoint Inhibitors/adverse effects ; Programmed Cell Death 1 Receptor/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management.
Autorzy:
Wang TF; Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Carrier M; Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Mar 04; Vol. 30 (3), pp. 3032-3046. Date of Electronic Publication: 2023 Mar 04.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Antineoplastic Agents, Immunological*/therapeutic use
Lung Neoplasms*/drug therapy
Kidney Neoplasms*/drug therapy
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Incidence ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.
Autorzy:
Yu L; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Xu J; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Qiao R; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Han B; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Zhong H; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Zhong R; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Mar; Vol. 12 (5), pp. 5372-5383. Date of Electronic Publication: 2022 Oct 17.
Typ publikacji:
Review; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lung Neoplasms*
Carcinoma, Non-Small-Cell Lung*/drug therapy
Antineoplastic Agents, Immunological*/therapeutic use
Small Cell Lung Carcinoma*/drug therapy
Humans ; Immune Checkpoint Inhibitors/adverse effects ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor ; China ; Paclitaxel/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States.
Autorzy:
Veluswamy R; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.; Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York City, New York, USA.; Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Hirsch FR; Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Taioli E; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.; Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Wisnivesky J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.; Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.; Division of Pulmonary and Critical Care Medicine, Icahn School of Medicine, New York City, New York, USA.
Strauss R; BeiGene Ltd, Emeryville, California, USA.
Harrough D; BeiGene Ltd, Emeryville, California, USA.
Tang B; BeiGene Ltd, Emeryville, California, USA.
Barnes G; BeiGene Ltd, Emeryville, California, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2022 Nov; Vol. 11 (22), pp. 4265-4272. Date of Electronic Publication: 2022 May 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents, Immunological*/therapeutic use
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Female ; Humans ; B7-H1 Antigen ; Immune Checkpoint Inhibitors/therapeutic use ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; United States/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
Autorzy:
Cozma A; Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Sporis ND; Department of Medical Oncology, Prof. Dr. I. Chiricuta Oncology Institute, 400015 Cluj-Napoca, Romania.
Lazar AL; Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Buruiana A; Department of Medical Oncology, Prof. Dr. I. Chiricuta Oncology Institute, 400015 Cluj-Napoca, Romania.
Ganea AM; Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Malinescu TV; Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Berechet BM; Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Fodor A; Clinical Centre of Diabetes, Nutrition and Metabolic Disease, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Sitar-Taut AV; Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Vlad VC; Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Negrean V; Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Orasan OH; Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Sep 19; Vol. 23 (18). Date of Electronic Publication: 2022 Sep 19.
Typ publikacji:
Journal Article; Review; Systematic Review
MeSH Terms:
Antineoplastic Agents, Immunological*/therapeutic use
Carcinoma, Hepatocellular*/chemically induced
Carcinoma, Non-Small-Cell Lung*/drug therapy
Drug-Related Side Effects and Adverse Reactions*
Liver Neoplasms*/chemically induced
Lung Neoplasms*/drug therapy
Myocarditis*/chemically induced
Apoptosis Regulatory Proteins ; B7-H1 Antigen ; CTLA-4 Antigen ; Cardiotoxicity/etiology ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Ligands ; Programmed Cell Death 1 Receptor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.
Autorzy:
Han X; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Meng M; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Zhang T; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Wang J; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Huang G; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Ni Y; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Li W; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Dai J; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Yang X; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Ye X; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong Province, China.
Pokaż więcej
Źródło:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2022 Sep; Vol. 18 (5), pp. 1440-1443.
Typ publikacji:
Case Reports
MeSH Terms:
Antineoplastic Agents, Immunological*/adverse effects
Carcinoma, Non-Small-Cell Lung*/complications
Hypophysitis*/complications
Kidney Neoplasms*/pathology
Lung Neoplasms*/pathology
Aged ; Antibodies, Monoclonal, Humanized ; Glucocorticoids/therapeutic use ; Humans ; Immune Checkpoint Inhibitors ; Male ; Middle Aged ; Nivolumab/therapeutic use ; Programmed Cell Death 1 Receptor ; Steroids/therapeutic use
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Autorzy:
Hou YL; Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Wang DY; Department of Radiation Oncology, University of California, San Francisco, California, USA.
Hu JX; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Tian RY; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Wang W; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Su Q; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Li H; Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.; Multidisciplinary Clinic Center of Ocular Vascular Disease, College of Optometry, Capital Medical University, Beijing, China.
Wang YL; Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Pokaż więcej
Źródło:
Ocular immunology and inflammation [Ocul Immunol Inflamm] 2022 Aug; Vol. 30 (6), pp. 1449-1459. Date of Electronic Publication: 2021 May 10.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Antineoplastic Agents, Immunological*/adverse effects
Lung Neoplasms*/drug therapy
Humans ; Programmed Cell Death 1 Receptor ; B7-H1 Antigen/therapeutic use ; Immune Checkpoint Inhibitors/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.
Autorzy:
Berry S; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Giraldo NA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Green BF; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Cottrell TR; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Stein JE; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Engle EL; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Xu H; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Ogurtsova A; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Roberts C; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Wang D; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Nguyen P; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Zhu Q; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Soto-Diaz S; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Loyola J; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Sander IB; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Wong PF; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Jessel S; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Doyle J; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Signer D; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Wilton R; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Roskes JS; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Eminizer M; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Park S; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Sunshine JC; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jaffee EM; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Baras A; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
De Marzo AM; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Topalian SL; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Kluger H; Division of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
Cope L; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Lipson EJ; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Danilova L; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Anders RA; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Pardoll DM; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Szalay AS; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Taube JM; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA. .; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Jun 11; Vol. 372 (6547).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Fluorescent Antibody Technique*
Antineoplastic Agents, Immunological/*therapeutic use
Biomarkers, Tumor/*analysis
Melanoma/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Adult ; Aged ; Aged, 80 and over ; Antigens, CD/analysis ; Antigens, Differentiation, Myelomonocytic/analysis ; B7-H1 Antigen/analysis ; CD8 Antigens/analysis ; Female ; Forkhead Transcription Factors/analysis ; Humans ; Immune Checkpoint Proteins/analysis ; Macrophages/chemistry ; Male ; Melanoma/chemistry ; Melanoma/immunology ; Melanoma/pathology ; Middle Aged ; Prognosis ; Programmed Cell Death 1 Receptor/analysis ; Progression-Free Survival ; Receptors, Cell Surface/analysis ; SOXE Transcription Factors/analysis ; Single-Cell Analysis ; T-Lymphocyte Subsets/chemistry ; T-Lymphocyte Subsets/immunology ; Treatment Outcome ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Autorzy:
Baruch EN; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel. .; Department of Clinical Immunology and Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Youngster I; Pediatric Division and the Microbiome Research Center, Shamir (Assaf Harofeh) Medical Center, Be'er Ya'akov, Israel.; School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ben-Betzalel G; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
Ortenberg R; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
Lahat A; Department of Gastroenterology, Sheba Medical Center, Tel HaShomer, Israel.
Katz L; Department of Gastroenterology, Hadassah Medical Center, Jerusalem, Israel.
Adler K; Department of Mathematics, Bar Ilan University, Ramat Gan, Israel.
Dick-Necula D; Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
Raskin S; School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Radiological Institute, Sheba Medical Center, Tel HaShomer, Israel.
Bloch N; Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Rotin D; Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
Anafi L; Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
Avivi C; Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
Melnichenko J; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
Steinberg-Silman Y; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
Mamtani R; Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Harati H; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
Asher N; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
Shapira-Frommer R; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
Brosh-Nissimov T; Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
Eshet Y; School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.; Department of Nuclear Medicine, Sheba Medical Center, Tel HaShomer, Israel.
Ben-Simon S; Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Ziv O; Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Khan MAW; Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amit M; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ajami NJ; Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Barshack I; School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
Schachter J; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.; School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Wargo JA; Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Koren O; Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Markel G; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel. .; Department of Clinical Immunology and Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Talpiot Medical Leadership Program, Sheba Medical Center, Tel HaShomer, Israel.
Boursi B; School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.; Department of Oncology, Sheba Medical Center, Tel HaShomer, Israel.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Feb 05; Vol. 371 (6529), pp. 602-609. Date of Electronic Publication: 2020 Dec 10.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gastrointestinal Microbiome*
Antineoplastic Agents, Immunological/*therapeutic use
Fecal Microbiota Transplantation/*adverse effects
Melanoma/*therapy
Nivolumab/*therapeutic use
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Skin Neoplasms/*therapy
Adult ; CD8-Positive T-Lymphocytes/immunology ; Female ; Humans ; Immunotherapy ; Intestinal Mucosa/immunology ; Intestinal Mucosa/microbiology ; Lymphocytes, Tumor-Infiltrating/immunology ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/immunology ; Transcriptome ; Tumor Microenvironment/genetics ; Tumor Microenvironment/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.
Autorzy:
Miyawaki T; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Naito T; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Doshita K; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Kodama H; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Mori M; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Nishioka N; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Iida Y; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Miyawaki E; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Mamesaya N; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Kobayashi H; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Omori S; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Ko R; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Wakuda K; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Ono A; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Kenmotsu H; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Mori K; Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
Harada H; Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan.
Endo M; Division of Diagnostic Radiology, Shizuoka Cancer Centre, Shizuoka, Japan.
Takahashi K; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2022 Jul; Vol. 13 (14), pp. 2064-2074. Date of Electronic Publication: 2022 Jun 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents, Immunological*/therapeutic use
Carcinoma, Non-Small-Cell Lung*/complications
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/complications
Lung Neoplasms*/drug therapy
B7-H1 Antigen/therapeutic use ; Cachexia/etiology ; Cachexia/therapy ; Humans ; Immunotherapy ; Programmed Cell Death 1 Receptor/therapeutic use ; Retrospective Studies ; Tumor Burden
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Autorzy:
Wu S; Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Biociències, Edifici Cs, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.
Calero-Pérez P; Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Biociències, Edifici Cs, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.; Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 09183 Cerdanyola del Vallès, Spain.
Arús C; Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Biociències, Edifici Cs, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.; Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 09183 Cerdanyola del Vallès, Spain.; Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.
Candiota AP; Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 09183 Cerdanyola del Vallès, Spain.; Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Biociències, Edifici Cs, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.; Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Nov 20; Vol. 21 (22). Date of Electronic Publication: 2020 Nov 20.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal/*pharmacology
Antineoplastic Agents, Alkylating/*pharmacology
Antineoplastic Agents, Immunological/*pharmacology
Brain Neoplasms/*drug therapy
Glioblastoma/*drug therapy
Programmed Cell Death 1 Receptor/*genetics
Temozolomide/*pharmacology
Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Biomarkers, Pharmacological ; Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/genetics ; Brain Neoplasms/mortality ; Drug Administration Schedule ; Drug Chronotherapy ; Drug Evaluation, Preclinical ; Female ; Gene Expression Regulation, Neoplastic ; Glioblastoma/diagnostic imaging ; Glioblastoma/genetics ; Glioblastoma/mortality ; Immunoglobulin G/pharmacology ; Immunologic Memory/drug effects ; Immunotherapy/methods ; Magnetic Resonance Spectroscopy ; Mice ; Mice, Inbred C57BL ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Survival Analysis ; Tumor Burden/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Deceleration in the rate of keratinocyte cancers and precancerous lesions during programmed death-1 inhibition therapy for advanced melanoma, with recrudescence on discontinuation.
Autorzy:
Roche L; Departments of Dermatology,, St Vincent's Healthcare Group Strategic Skin Cancer Network, St Vincent's University Hospital, Dublin, Ireland.
Moriarty B; Departments of Dermatology,, St Vincent's Healthcare Group Strategic Skin Cancer Network, St Vincent's University Hospital, Dublin, Ireland.
Fabre A; Histopathology, St Vincent's Healthcare Group Strategic Skin Cancer Network, St Vincent's University Hospital, Dublin, Ireland.
Crowne J; Medical Oncology, St Vincent's Healthcare Group Strategic Skin Cancer Network, St Vincent's University Hospital, Dublin, Ireland.
Lally A; Departments of Dermatology,, St Vincent's Healthcare Group Strategic Skin Cancer Network, St Vincent's University Hospital, Dublin, Ireland.
Pokaż więcej
Źródło:
Clinical and experimental dermatology [Clin Exp Dermatol] 2022 Mar; Vol. 47 (3), pp. 582-584. Date of Electronic Publication: 2021 Dec 28.
Typ publikacji:
Case Reports; Letter
MeSH Terms:
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Melanoma/*drug therapy
Precancerous Conditions/*diagnosis
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Skin Neoplasms/*diagnosis
Skin Neoplasms/*drug therapy
Aged ; Aged, 80 and over ; Carcinoma, Basal Cell/diagnosis ; Carcinoma, Squamous Cell/diagnosis ; Female ; Humans ; Keratinocytes/pathology ; Melanoma/pathology ; Neoplasm Recurrence, Local ; Skin Neoplasms/pathology ; Withholding Treatment
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.
Autorzy:
Breimer LH; Centre for Assessment of Medical Technology in Örebro, School of Health and Medical Sciences, Örebro University, Örebro University Hospital, Örebro, Sweden.; Department of Laboratory Medicine, Clinical Chemistry Division, Örebro University Hospital, Örebro, Sweden.
Nousios P; Centre for Assessment of Medical Technology in Örebro, School of Health and Medical Sciences, Örebro University, Örebro University Hospital, Örebro, Sweden.
Olsson L; Centre for Assessment of Medical Technology in Örebro, School of Health and Medical Sciences, Örebro University, Örebro University Hospital, Örebro, Sweden.
Brunnström H; Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.
Pokaż więcej
Źródło:
Scandinavian journal of clinical and laboratory investigation [Scand J Clin Lab Invest] 2020 Sep; Vol. 80 (5), pp. 360-369. Date of Electronic Publication: 2020 Apr 02.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents, Immunological/*administration & dosage
B7-H1 Antigen/*antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung/*drug therapy
Immune Checkpoint Inhibitors/*administration & dosage
Lung Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/economics ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/economics ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/economics ; B7-H1 Antigen/genetics ; B7-H1 Antigen/immunology ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/genetics ; CTLA-4 Antigen/immunology ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; Cost-Benefit Analysis ; Gene Expression Regulation, Neoplastic ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/economics ; Lung Neoplasms/genetics ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Nivolumab/administration & dosage ; Nivolumab/adverse effects ; Nivolumab/economics ; Programmed Cell Death 1 Receptor/genetics ; Programmed Cell Death 1 Receptor/immunology ; Randomized Controlled Trials as Topic ; Signal Transduction ; Survival Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma.
Autorzy:
Ohashi H; Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Takeuchi S; Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Miyagaki T; Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Kadono T; Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Pokaż więcej
Źródło:
Drug discoveries & therapeutics [Drug Discov Ther] 2020 Jul 15; Vol. 14 (3), pp. 117-121. Date of Electronic Publication: 2020 Jun 27.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Agents, Immunological/*administration & dosage
Melanoma/*drug therapy
Nivolumab/*administration & dosage
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Skin Neoplasms/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Autoantibodies/blood ; Autoantibodies/drug effects ; Eosinophils/drug effects ; Eosinophils/metabolism ; Female ; Humans ; Lymphocytes/drug effects ; Lymphocytes/metabolism ; Male ; Melanoma/blood ; Middle Aged ; Neoplasm Staging/methods ; Neutrophils/drug effects ; Neutrophils/metabolism ; Programmed Cell Death 1 Receptor/blood ; Retrospective Studies ; Skin Neoplasms/blood ; Treatment Outcome ; Melanoma, Cutaneous Malignant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
Autorzy:
De Filippi R; Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi Federico II, Napoli, Italy.; Ematologia Oncologica e Trapianto di Cellule Staminali, Department of Hematology and Developmental Therapeutics, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 49, 80131, Naples, Italy.
Morabito F; Hemato-Oncology Department, Augusta Victoria Hospital, East Jerusalem, Israel.; Unità di Ricerca Biotecnologica, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
Santoro A; Humanitas University, Milano, Italy.; IRCCS Humanitas Research Hospital, Milano, Italy.
Tripepi G; Unità di Ricerca CNR-IFC, Reggio Calabria, Italy.
D'Alò F; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.; Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy.
Rigacci L; Ematologia e Trapianto di Cellule Staminali, A.O. San Camillo Forlanini, Roma, Italy.
Ricci F; Humanitas University, Milano, Italy.; IRCCS Humanitas Research Hospital, Milano, Italy.
Morelli E; Ematologia Oncologica e Trapianto di Cellule Staminali, Department of Hematology and Developmental Therapeutics, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 49, 80131, Naples, Italy.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy.
Pinto A; Ematologia Oncologica e Trapianto di Cellule Staminali, Department of Hematology and Developmental Therapeutics, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 49, 80131, Naples, Italy. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2021 Dec 01; Vol. 19 (1), pp. 489. Date of Electronic Publication: 2021 Dec 01.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents, Immunological*/therapeutic use
Hodgkin Disease*/complications
Hodgkin Disease*/drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Body Mass Index ; Female ; Humans ; Immune Checkpoint Inhibitors ; Male ; Middle Aged ; Nivolumab/adverse effects ; Programmed Cell Death 1 Receptor ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cemiplimab in advanced cutaneous squamous cell carcinoma.
Autorzy:
Naik PP; Department of Dermatology, Saudi German Hospital and Clinic, Dubai, United Arab Emirates.
Pokaż więcej
Źródło:
Dermatologic therapy [Dermatol Ther] 2021 Nov; Vol. 34 (6), pp. e15184. Date of Electronic Publication: 2021 Nov 08.
Typ publikacji:
Journal Article; Review; Systematic Review
MeSH Terms:
Antineoplastic Agents, Immunological*/adverse effects
Antineoplastic Agents, Immunological*/therapeutic use
Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/pathology
Skin Neoplasms*/drug therapy
Skin Neoplasms*/pathology
Antibodies, Monoclonal, Humanized ; Humans ; Programmed Cell Death 1 Receptor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
Autorzy:
Yoshida K; Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Okamoto M; Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan. .
Sasaki J; Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Kuroda C; Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Ishida H; Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Ueda K; Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Ideta H; Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Kamanaka T; Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Sobajima A; Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Takizawa T; Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Tanaka M; Department of Orthopedic Surgery, Okaya City Hospital, Okaya, Japan.
Aoki K; Physical Therapy Division, School of Health Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
Uemura T; Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Kato H; Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Haniu H; Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Saito N; Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Asahi 3-1-1, Matsumoto, 390-8621, Japan. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 Jan 08; Vol. 20 (1), pp. 25. Date of Electronic Publication: 2020 Jan 08.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents, Immunological/*pharmacology
Lymphocytes, Tumor-Infiltrating/*drug effects
Lymphocytes, Tumor-Infiltrating/*metabolism
Neoplasms/*immunology
Neoplasms/*metabolism
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
T-Lymphocytes, Regulatory/*drug effects
T-Lymphocytes, Regulatory/*metabolism
Animals ; Antineoplastic Agents, Immunological/therapeutic use ; Cell Line, Tumor ; Disease Models, Animal ; Gene Expression ; Humans ; Interferon-gamma/metabolism ; Lymphocytes, Tumor-Infiltrating/immunology ; Mice ; Neoplasms/mortality ; Neoplasms/pathology ; Prognosis ; Programmed Cell Death 1 Receptor/genetics ; Programmed Cell Death 1 Receptor/metabolism ; T-Lymphocytes, Regulatory/immunology ; Treatment Outcome ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 153

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies